In Mesa, Arizona, a non-profit organization dedicated to the care of opioid-exposed infants is facing a severe financial crisis that may lead to its shutdown. Jacob's Hope, which has been crucial in providing specialty care to newborns struggling with opioid withdrawal, is grappling with insufficient funds due to low reimbursement rates, a shortfall in private donations, and significant care provider costs. The organization claims that Arizona Health Care Cost Containment System (AHCCCS) is holding back over $80,000 in payments, putting the nonprofit at risk of closing its inpatient facility, according to a report by AZFamily.
Jo Jones, the founder and executive director of Jacob's Hope, conveyed the gravity of the situation stating, "Intervention care is life-changing for these babies and can change the trajectory of their lives," detailing the significant impact the nonprofit has in the context of the ongoing opioid crisis, Jacob's Hope estimated that with full funding they could extend their life-altering support to hundreds of infants and their families but the lack of financial stability has left them with no choice but to consider shutting down. For those interested in supporting Jacob's Hope, a link to donate has been provided by AZFamily.
Meanwhile, on a broader scale, the Advancing Clinical Trials in Neonatal Opioid Withdrawal Syndrome (ACT NOW) Program, part of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, has been working since 2017 to develop evidence-based treatments for Neonatal Opioid Withdrawal Syndrome (NOWS) or neonatal abstinence syndrome through rigorous clinical trials. The need for such research is underscored by data showing a rise in the rate of neonatal abstinence syndrome from 4.0 to 7.3 per 1,000 birth hospitalizations between 2010 and 2017. Yet despite the increased occurrence of NOWS, standard treatments are lacking and the long-term effects remain relatively unknown as reported by NIH HEAL Initiative.
ACT NOW is currently invested in trials including the ESC Clinical Trial, which focuses on non-pharmacologic care over opioid usage for infants with NOWS and is aiming to determine which treatment strategies provide the best outcomes for infants while the Weaning Trial compares methods of opioid weaning for newborns treated with morphine or methadone, and finally, the Longitudinal Study, which is examining the impact of prenatal opioid exposure on early childhood outcomes. With a commitment of $69.4 million from the NIH HEAL Initiative, this program is poised to contribute vital knowledge that can inform medical practice and ultimately, provide affected infants with the best start in life, as outlined by the NIH HEAL Initiative.
